Seton or Glue for Trans-sphincteric Anal Fistulas

This study has been terminated.
(Evident advantages of one treatment (seton) over the other (Tissucol Glue))
Sponsor:
Information provided by:
Societa Italiana di Chirurgia ColoRettale
ClinicalTrials.gov Identifier:
NCT00929630
First received: March 30, 2009
Last updated: September 15, 2009
Last verified: September 2009

March 30, 2009
September 15, 2009
January 2006
May 2007   (final data collection date for primary outcome measure)
Fistula healing (absence of any discharge from the external fistula opening and complete healing of the external fistulas opening after at least 1 year of follow-up). The analysis of the population is not intention to treat. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00929630 on ClinicalTrials.gov Archive Site
Fecal continence and in-hospital stay [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Seton or Glue for Trans-sphincteric Anal Fistulas
Seton or Glue for Trans-sphincteric Anal Fistulas. A Prospective Randomised Clinical Trial

Surgical treatment of perianal fistulas frequently affects fecal continence. Sphincter saving techniques like loose or cutting seton and fistulectomy with advancement of an endorectal flap have been advocated to minimize the risk of sphincter injury, but patients often complain of a prolonged healing period and major discomfort. Furthermore, the healing rate varies widely according to the type of fistula and the surgeon's experience.In the early '90s the treatment of perianal fistulas by autologous or commercial fibrin glue was suggested and the American FDA approved the use and marketing of a human fibrin glue in 1998.

Since then, several studies have evaluated the effectiveness of human fibrin glue in the treatment of different types of perianal fistulas, reporting a wide range of success rates ranging from 31 to 85%.

Primary aim of this study is to conduct a prospective randomized trial evaluating the effectiveness of glue treatment of perianal fistulas as compared with the classical seton treatment. Secondary aims are to compare postoperative faecal incontinence, postoperative anal pain, healing time and length of hospitalization.

Background: Fibrin glue treatment of anal fistulas has been proposed to minimize the risk of faecal incontinence but its acceptance by coloproctologists is still poor because clear data in literature are lacking. We will run a prospective randomised trial comparing commercial fibrin glue treatment with classical seton treatment, taking into account the healing rate, hospital stay, healing time, faecal incontinence and postoperative pain.

Patients and Methods: 130 homogeneous patients with trans-sphincteric anal fistulas referred to 7 Colorectal Units will be randomised to undergo fibrin glue or seton treatment. permanent healing of the fistula will be defined as absence on any discharge from the fistula and healing of the secondary fistula orifice after at least 1 year of follow up.

Post operative pain (on a VAS scale) and hospital stay will be recorded and compared in the two groups

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Anal Fistulas
  • Procedure: transsphincteric Seton positioning
    A cutting seton is applied into the fistula tract
    Other Name: seton treatment of the fistula
  • Procedure: glue (Tissucol) treatment
    After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
    Other Name: fibrin glue treatment of perianal fistulas
  • Procedure: Fistula closing with biological glue
    After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
    Other Name: fibrin glue treatment of perianal fistulas
  • Procedure: Seton positioning into the fistula tract
    Under spinal anesthesia a Seton is positioned into the fistula tract.
    Other Name: loose seton, cutting seton for anal fistulas
  • Experimental: glue (Tissucol ) treatment
    patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
    Interventions:
    • Procedure: glue (Tissucol) treatment
    • Procedure: Fistula closing with biological glue
  • Active Comparator: Seton treatment
    patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
    Interventions:
    • Procedure: transsphincteric Seton positioning
    • Procedure: Seton positioning into the fistula tract
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
65
June 2007
May 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • medium or high trans-sphincteric fistulas of cryptoglandular origin, no previous treatments

Exclusion Criteria:

  • Crohn's disease
  • anal abscesses
  • complex fistulas (horse-shoe type or multiple secondary tracts)
  • immunosuppression
  • diabetes,
  • anal fissures
  • pregnancy
  • anti-coagulant treatments,
  • any allergic reaction to the bioglue components.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT00929630
SICCR 10/2006
Yes
Donato F Altomare, Italian Society of Colorectal surgery
Societa Italiana di Chirurgia ColoRettale
Not Provided
Principal Investigator: Donato F Altomare, MD University of Bari, Italy
Societa Italiana di Chirurgia ColoRettale
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP